is glimepiride a glp-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease GLP-1 Drug Interactions: Hidden Risks

Wegovy is an FDA-approved semaglutide option for chronic weight management in eligible patients, and Zepbound is an FDA-approved tirzepatide option for chronic weight management in eligible patients

Approximately 20% of the oral dose (and probably most of the absorbed dose) is excreted within 24 h (Ray, 1991)

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

A recent clinical trial has found that in patients with T2DM, tirzepatide performed better than GLP1RAs and dulaglutide monotherapy regarding glycaemic management and body weight reduction

At Livglam, Dr Harish is committed to delivering safe, effective, and personalised treatments, ensuring every patients journey is smooth, comfortable, and results-driven